Menu
Search
|

Menu

Close
X

Altimmune Inc ALT.OQ (NASDAQ Stock Exchange Global Market)

1.53 USD
+0.02 (+1.32%)
As of Feb 23
chart
Previous Close 1.51
Open 1.48
Volume 10,124
3m Avg Volume 33,710
Today’s High 1.53
Today’s Low 1.46
52 Week High 10.80
52 Week Low 1.38
Shares Outstanding (mil) 15.65
Market Capitalization (mil) 23.79
Forward P/E 0.18
Dividend (Yield %) 29.10 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
8
FY16
3
FY15
11
EPS (USD)
FY17
-2.993
FY16
10.401
FY15
-0.537
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
0.18
33.62
Price to Sales (TTM)
vs sector
2.63
8.35
Price to Book (MRQ)
vs sector
0.49
5.22
Price to Cash Flow (TTM)
vs sector
0.62
25.88
Total Debt to Equity (MRQ)
vs sector
1.12
15.84
LT Debt to Equity (MRQ)
vs sector
1.03
12.39
Return on Investment (TTM)
vs sector
38.85
13.63
Return on Equity (TTM)
vs sector
41.12
15.39

EXECUTIVE LEADERSHIP

Mitchel Sayare
Chairman of the Board, Since 2018
Salary: --
Bonus: --
William Enright
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Elizabeth Czerepak
Chief Financial Officer, Executive Vice President - Corporate Development, Since 2017
Salary: --
Bonus: --
M. Scot Roberts
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --
Sybil Tasker
Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

19 Firstfield Rd
GAITHERSBURG   MD   20878-1791

Phone: +1240.6541450

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape.

SPONSORED STORIES